A comparison of low-dose and normal-dose gadobutrol in MR renography and renal angiography

Clinical Efficacy of Reduced Dose Gadobutrol Versus Standard Dose Gadoterate for Contrast-Enhanced MRI of the CNS: An International Multicenter Prospective Crossover Trial (LEADER-75)

Background: Gadobutrol and gadoterate are widely used macrocyclic gadolinium-based contrast agents. Given gadobutrol's higher T1 relaxivity, reduced gadobutrol dose should achieve essentially equivalent diagnostic efficacy as standard gadoterate dose. Objective: To demonstrate that efficacy of 25%-reduced dose of gadobutrol (rd-gadobutrol) is non-inferior to 100%-standard-dose of gadoterate (sd-gadoterate) for contrast-enhanced MRI of the CNS. Methods: In this international, prospective, multicenter, open-label, cross-over trial (LEADER-75), adult patients with known or suspected CNS pathology underwent contrast-enhanced brain MRI with sd-gadoterate (0.1 mmol/kg); if an enhancing lesion was identified, a second MRI with rd-gadobutrol (0.075 mmol/kg) was performed within 15 days. Three radiologists independently reviewed images to score three primary efficacy measures (subjective lesion enhancement, lesion border delineation, lesion internal morphology); primary non-inferiority analysis used readers' mean scores. Non-inferiority of rd-gadobutrol to sd-gadoterate for primary efficacy measures was defined as difference in score between rd-gadobutrol and unenhanced images achieving at least 80% of difference in score between sd-gadoterate and unenhanced images. Post-hoc analysis was performed to directly compare contrast-enhanced images for equivalence. Secondary efficacy variables included number of lesions detected, reader confidence, diagnostic performance for malignancy, and reader preference in side-by-side comparison. Results: The efficacy analysis included 141 patients (78 men, 63 women; mean age, 58.5±13.5 years). Improvement of rd-gadobutrol over unenhanced images was non-inferior to improvement of sd-gadoterate over unenhanced images using 20% non-inferiority margin for all three primary efficacy measures using mean readings (p≤.025). In post-hoc analysis, mean reading for the three primary efficacy measures differed by less than 1% between rd-gadobutrol and sd-gadoterate, supporting equivalence of all measures using a narrow ±5% margin (p≤.025). Total lesions detected by mean reading was 301 for rd-gadobutrol versus 291 for sd-gadoterate. Mean confidence was 3.3±0.6 for rd-gadobutrol versus 3.3±0.6 for sd-gadoterate. Sensitivity (58.7%), specificity (91.8%), and accuracy (70.2%) for malignancy from majority reading were identical for rd-gadobutrol and sd-gadoterate. Reader preference was not different (95% CI [-0.10, 0.11]). Conclusion: A 25%-reduced dose of gadobutrol is non-inferior to sd-gadoterate for contrast-enhanced brain MRI. Clinical Impact: Use of rd-gadobutrol should be considered for brain MRI, particularly in patients undergoing multiple contrast-enhanced examinations.

A comparison of the use of contrast media with different iodine concentrations for multidetector CT of the kidney

Objective

To determine the optimal iodine concentration of contrast media for kidney multidetector computed tomography (MDCT) by comparing the degree of renal parenchymal enhancement and the severity of the renal streak artifact with contrast media of different iodine concentrations.

Materials and Methods

A 16-row MDCT was performed in 15 sedated rabbits by injection of 2 mL contrast media/kg body weight at a rate of 0.3 mL/sec. Monomeric nonionic contrast media of 250, 300, and 370 mg iodine/mL were injected at 1-week intervals. Mean attenuation values were measured in each renal structure with attenuation differences among the structures. The artifact was evaluated by CT window width/level and three grading methods. The values were compared with iodine concentrations.

Results

The 370 mg iodine/mL concentration showed significantly higher cortical enhancement than 250 mg iodine/mL in all phases (p < 0.05). There was however no significant difference in the degree of enhancement between the 300 mg iodine/mL and 370 mg iodine/mL concentrations in all phases. There is a significant difference in attenuation for the cortex-outer medulla between 250 mg iodine/mL and 300 mg iodine/mL (p < 0.05). The artifact was more severe with a medium of 370 mg iodine/mL than with 250 mg iodine/mL by all grading methods (p < 0.05).

Conclusion

The 300 mg iodine/mL is considered to be the most appropriate iodine concentration in an aspect of the enhancement and artifact on a kidney MDCT scan.